Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” [Breast 41S1 (2018) S11–12]

Shranjeno v:
Bibliografske podrobnosti
izdano v:Breast
Main Authors: Cristofanilli, Massimo, Harbeck, Nadia, Rugo, Hope S., Castrellon, Aurelio, Joy, Anil Abraham, Verma, Sunil, Im, Seock-Ah, Iyer, Shrividya, Puyana Theall, Kathy, Gauthier, Eric, Huang, Xin, Bartlett, Cynthia Huang, Loibl, Sibylle, Finn, Richard S.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2019
Teme:
Corrigendum
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7375617/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2019.11.010
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki